PHPBiotech.wikiThe PHP Biotech Reference

PHP Biotech

From PHPBiotech.wiki, a sourced reference on PHP Biotech, a preclinical oncology company

By the PHP Biotech Wiki editorial team · Published · Last updated

Short answer: PHP Biotech (legal name PHP Biotech International Inc.) is a preclinical biotechnology company developing PHP53-nb, an experimental cancer drug candidate made from a nanobody that carries a peptide called 3-NAntC.[1][2] The company says it plans to finish preclinical studies in 2026 and hopes to begin clinical trials in 2027; no clinical trial is registered as of 4 October 2026.[2][3] PHP53-nb has not been approved by the U.S. Food and Drug Administration or any other regulator.[4]

Disclosure: PHPBiotech.wiki is a reference compiled from public sources. It is not the official website of PHP Biotech International Inc.; it is produced by a marketing agency that works for PHP Biotech. It is not written or reviewed by the U.S. Food and Drug Administration or any other regulator, by the journal that published the company’s research, or by any patent office. Nothing on this site is medical advice. PHP53-nb is an investigational, preclinical product: it is not approved for any use and is not available to patients. Facts are cited to public registries, PubMed, patent records, archived web pages, press releases and the company’s own website. See the editorial policy.

PHP Biotech describes itself as a U.S.-based platform biotechnology company focused on oncology, with research aimed at restoring the function of the p53 tumor-suppressor pathway in cancer cells.[1][10] Its website lists a business address in Southlake, Texas, while a 2024 research paper by its scientists gives Keller, Texas, and a Brazilian company with the PHP Biotech name is registered in Botucatu, São Paulo.[1][7][8] This wiki does not choose between these locations; see Corporate records and locations.

This page summarizes what public records show and what the company says about itself. Each section links to a longer article.

What is PHP Biotech developing?

The company’s lead candidate is PHP53-nb, which it describes as a humanized camelid nanobody (a small antibody fragment) that carries the peptide 3-NAntC inside its binding region, without chemical linkers.[2][6] 3-NAntC is a synthetic peptide derived from crotoxin B, a protein from rattlesnake venom.[7] The company builds such molecules on what it calls the GEN01-AD platform.[6] See PHP53-nb and GEN01-AD platform.

Is PHP Biotech in clinical trials?

No. A search of ClinicalTrials.gov on 4 October 2026 found no studies of PHP53-nb, 3-NAntC or Pepcrotament, and none sponsored by PHP Biotech.[3] The company’s own science page says it plans to finish preclinical studies in 2026 and hopes to start clinical trials in 2027.[2] The company notes that results so far come from model systems and preclinical research.[11] See Development stage.

What research has been published?

One peer-reviewed paper was found: a 2024 study in the journal Molecules by Patrícia Bezerra and Eduardo Motti, which tested the 3-NAntC peptide on its own in breast cancer cells in the laboratory and in zebrafish.[7] The authors state they are employed by PHP Biotech International Inc., which fully funded the work.[7] Other data the company describes, such as mouse and zebrafish studies of PHP53-nb, appear on its website and in press releases, and this wiki found no peer-reviewed publication of them.[2][4] See Patents and publications.

Does PHP Biotech have patents?

Two U.S. patent applications assigned to PHP Biotech International Inc. have been published: US 2023/0364204 A1 on the peptides and US 2026/0041783 A1 on the nanobody platform. Google Patents lists both as pending.[5][12] The company says it has four U.S. patent applications.[11] See Patents and publications.

Who runs PHP Biotech?

The company lists Robert Gahagen as chief executive officer, Eduardo Motti, MD, as chief operating officer, João Marcelo Carucci as chief financial officer and Patrícia Bezerra, PhD, as head of research and development, with founder Moacyr Bighetti on its executive committee.[9] Bighetti and Bezerra are the named inventors on both published patent applications.[5][12] See Leadership and team.

What does the company claim, and what is verified?

The company’s home page says PHP53-nb restores the p53 pathway, with a note that this refers to model systems, and calls PHP53-nb “a patented nanobody”.[1] The published patent records show applications that are still pending, and the laboratory results have not been tested in people.[5][12][3] See Company claims in context.

Frequently asked questions

What is PHP Biotech?

A preclinical oncology biotechnology company, legal name PHP Biotech International Inc., developing the nanobody drug candidate PHP53-nb. It has no registered clinical trials as of 4 October 2026.

Is PHP53-nb available to patients?

No. PHP53-nb is investigational, has not been approved by the U.S. Food and Drug Administration or any other regulator, and has not entered clinical trials. Nothing on this site is medical advice.

Where is PHP Biotech located?

Its website gives 550 Reserve St. STE 190, Southlake, Texas. A 2024 paper gives Keller, Texas, and a related-name company is registered in Botucatu, Brazil. The official headquarters has not been confirmed.

Is PHP Biotech a public company?

No SEC filings were found for PHP Biotech in EDGAR as of 4 October 2026.

Is this the official PHP Biotech website?

No. The official website is phpbiotech.com. This reference site is produced by a marketing agency that works for PHP Biotech.

See also

References

  1. ^ a b c d e f g Home page. PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  2. ^ a b c d e f g “Our Science” (including the science FAQ). PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  3. ^ a b c d e ClinicalTrials.gov search results for “PHP53-nb”, “PHP53”, “Pepcrotament”, “3-NAntC” and sponsor “PHP Biotech” (no studies found). U.S. National Library of Medicine, ClinicalTrials.gov. Retrieved 4 October 2026.
  4. ^ a b c “PHP Biotech Identifies uPAR as the Cellular Entry Receptor for Its PHP53-nb Anti-Tumor Nanobody” (Southlake, Texas, 18 September 2026). PressAdvantage newsroom (company press release). Retrieved 4 October 2026.
  5. ^ a b c d US 2023/0364204 A1, “Bioactive Peptides, Compositions, Production Process, and Use of Bioactive Peptides as Anti-Tumoral Agents” (application 18/313,141). Google Patents (U.S. Patent and Trademark Office data). Retrieved 4 October 2026.
  6. ^ a b c “Platform”. PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  7. ^ a b c d e Bezerra P, Motti EF. “3-NAntC: A Potent Crotoxin B-Derived Peptide against the Triple-Negative MDA-MB-231 Breast Cancer Cell Line.” Molecules 2024;29(7):1646. doi:10.3390/molecules29071646. PMID 38611925. PubMed, U.S. National Library of Medicine. Retrieved 4 October 2026.
  8. ^ a b CNPJ 40.622.810/0001-02: PHP Biotech Pesquisa e Desenvolvimento S.A. (company registration record). Receita Federal do Brasil, via the BrasilAPI CNPJ service. Retrieved 4 October 2026.
  9. ^ a b c “Our Team”. PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  10. ^ “The p53 Tumor Suppressor, Explained” (blog post, 25 August 2026). PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  11. ^ a b “What Is a Nanobody?” (blog post, 17 August 2026). PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  12. ^ a b c US 2026/0041783 A1, “Nanobody platform, Peptide-modified Nanobody, Production Process, and Use” (application 19/223,678). Google Patents (U.S. Patent and Trademark Office data). Retrieved 4 October 2026.